Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $9.08M fell 85.4% year over year, ahead of the -193.6% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Net change in cash amounted to 22.1% of revenue in FY2025.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -85.4% holds above the trailing-twelve-month pace of -193.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (15.44M) USD
- Year-over-year change
- +22.0%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.44M) | +22.0% |
| FY2024 | 2024-12-31 | (19.79M) | -191.8% |
| FY2023 | 2023-12-31 | 21.56M | +168.4% |
| FY2022 | 2022-12-31 | (31.54M) | -201.1% |
| FY2021 | 2021-12-31 | 31.19M | — |
Net Change in Cash vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -193.6% is the 10th highest of 11, against a peer median of +149.5%.
- Over three fiscal years its annual growth of -21.2% compares with a peer median of +19.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $100M USD | -769.9% | +42.0% | 169491.5% | |
| LTM Mar 2026 | $68.35M USD | -193.6% | -21.2% | — | |
| LTM Mar 2026 | $45.1M USD | +2880.5% | — | 310.2% | |
| LTM Mar 2026 | $35.93M USD | +89.5% | +8.8% | — | |
| LTM Mar 2026 | $27.89M USD | +253.0% | — | 98.8% | |
| LTM Mar 2026 | $27.12M USD | +568.0% | +19.1% | 12051.1% | |
| LTM Mar 2026 | $25.29M USD | +542.2% | -17.4% | 36.5% | |
| LTM Mar 2026 | $17.5M USD | +161.4% | +56.0% | 34.3% | |
| LTM Mar 2026 | $17.36M USD | -13.1% | -72.2% | 155.0% | |
| FY2025 | €14.17M EUR | -79.7% | +326.2% | 316.0% | |
| LTM Mar 2026 | $11.46M USD | +137.7% | — | — | |
| Peer median (excluding BDTX) | — | +149.5% | +19.1% | 232.6% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| Deferred Income Tax | 2.18M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M |
| Change in Working Capital | 7.02M | (9.9M) | 3.69M | (2.69M) | (8.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (2.23M) | 597K | 1.68M | (3.43M) |
| Other Working Capital | 5.45M | (7.67M) | 3.09M | (4.38M) | (5.3M) |
| Other Non-Cash Items | 2.01M | 3.28M | 2M | (905K) | 9.02M |
| Operating Cash Flow | (100.15M) | (85.08M) | (66.72M) | (62.3M) | 29.61M |
| Capital Expenditures | (2.71M) | (192K) | (33K) | 0 | 0 |
| Acquisitions (Net) | 2.7M | 9K | 0 | 94K | 27K |
| Purchases of Investments | (49.51M) | (60.14M) | (61.89M) | (122.88M) | (164.03M) |
| Sales of Investments | 182.83M | 113.69M | 78.17M | 139.75M | 119.02M |
| Other Investing Activities | (2.7M) | 0 | 95K | 0 | 74K |
| Investing Cash Flow | 130.61M | 53.37M | 16.35M | 16.97M | (44.91M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 729K | 177K | 71.85M | 24.49M | (146K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 82K | 1.05M | 0 |
| Financing Cash Flow | 729K | 177K | 71.93M | 25.55M | (146K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.19M | (31.54M) | 21.56M | (19.79M) | (15.44M) |
| Free Cash Flow | (102.86M) | (85.27M) | (66.75M) | (62.3M) | 29.61M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.